VIR Vir Biotechnology, Inc. Common Stock
XNAS
10.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VIR
$10.21
—
Key stats
$10.21
- 52-Week Range
- $4.82 – $12.00
- YTD
- +71.83%
- IV Rank (30D)
- 65.03
- Straddle Price
- $2.03
- P/C Vol Ratio
- 0.23
- Market Cap
- $1.8B
- Open
- $10.51
- Day Range
- $10.18 – $10.75
- Volume
- 409,042
- Prev Close
- $10.57
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.83 |
| Cost of Equity (CAPM) | 9.28% (VRP-adj) |
| WACC | 9.27% |
| Volatility Risk Premium | +74.8pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -25.6% |
| Book / Price | 62.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -67.1% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $10.67 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.91 |
| Bollinger Width / SMA20 | 169.9% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $2B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$29.60
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.1× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 8 peers |
| Peer P/B | $75.93 | 27% | median 11.5× · 10 peers |
| Peer P/S | $14.72 | 27% | median 6.5× · 9 peers |
| Market Anchor (SMA50) | $10.67 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $10.73 | 45% | 13 strikes · skew -0.07 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $1.8B
- Employees
- 367
- List Date
- 2019-10-11
- CIK
- 0001706431
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.80) (5 est.)
- Headquarters
- San Francisco, CA
- Homepage
- https://www.vir.bio
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 141.27% | -12.87% | 18.58% | -10.56% | 43.05% | 25.25% | 34.12% |
| Feb | -5.75% | -28.40% | -21.81% | 23.25% | -15.93% | 17.90% | -5.12% |
| Mar | -23.17% | 7.17% | 2.96% | -9.88% | -18.18% | -4.07% | -7.53% |
| Apr | -3.69% | -19.57% | 8.03% | -17.06% | -0.97% | 13.25% | -3.33% |
| May | -9.54% | 23.73% | 6.00% | 17.51% | -18.75% | -4.60% | 2.39% |
| Jun | 13.63% | -0.20% | -8.78% | -16.27% | -0.59% | 12.85% | 0.11% |
| Jul | -18.10% | 7.50% | -42.81% | 11.65% | -0.78% | -9.65% | -8.70% |
| Aug | 43.73% | -13.42% | -11.10% | -15.11% | -1.79% | 22.92% | 4.21% |
| Sep | -8.38% | -20.79% | -25.10% | -3.73% | 14.20% | -3.87% | -7.95% |
| Oct | 9.84% | 10.12% | -11.79% | -0.93% | 4.56% | -9.30%* | 0.42% |
| Nov | 28.16% | 25.31% | 21.82% | -14.04% | 14.64% | -- | 15.18% |
| Dec | -10.86% | -6.36% | 3.82% | -9.94% | -0.66% | -- | -4.80% |
| Total | 134.07% | -36.74% | -57.64% | -43.27% | 4.29% | 67.24% | 11.33% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.88
SMA 50: $10.70
SMA 200: $9.36
Current: $10.24
EMA 12: $10.63
EMA 26: $10.74
MACD: -0.1062 | Signal: -0.1127
BULLISH
ADX (14): 15.65
RANGE
+DI: 20.02
−DI: 22.33
Momentum Oscillators
RSI (14): 44.05
NEUTRAL
Stoch %K: 29.11
Stoch %D: 25.49
Williams %R: -83.97
Volume & Volatility
BB Upper: $11.93
BB Lower: $9.84
NEUTRAL
OBV: 64,055,796
Vol SMA 20: 1,894,711
Vol ROC: -86.78%
ATR: $0.61
True Range: $0.57
HV 20: 54.4%
HV 30: 52.8%
HV 60: 51.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
VIR (Vir Biotechnology) - Comprehensive Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with 5.8/10 confidence level
Vir Biotechnology presents a conflicted technical and fundamental picture amid a strong recent rally. While the stock has appreciated significantly (referenced 99% biotech fund rally context), current price action shows exhaustion signals—trading 5.7% below its 20-day moving average with oversold Bollinger Bands and extreme Stochastic readings. The recent Gilead partnership news (2026-10-15) provides fundamental support, but elevated valuations and weak momentum divergence warrant caution.
Key Drivers:
- Positive: Gilead oncology pipeline deal, immune-priming therapy developments, recent fund accumulation
- Primary Risks: High beta (1.75) volatility, overbought conditions prior to current pullback, low IV rank suggesting compressed option pricing, mixed momentum signals
Investment Thesis: VIR is a high-risk biotech name in consolidation mode following a strong rally. Recent partnership news validates clinical progress, but current technical setup suggests near-term weakness before potential accumulation. The risk/reward is asymmetric to the downside given current positioning and low correlation (0.34) to broader market dynamics.
Recent News Sentiment Impact: Positive sentiment (4 of 5 recent headlines bullish) provided tailwinds, but timing of the major rally preceding current pullback suggests institutional money may be taking profits ahead of November 4th earnings.
Technical Analysis
Trend Direction
| Timeframe | Direction | Confidence | Key Signal | |-----------|-----------|------------|-----------| | Short-term (1-4 weeks) | DOWNTREND | Medium | Price $9.96 trading 9.5% below SMA 20 ($11.01); below EMA 12 ($10.81) | | Medium-term (1-3 months) | SIDEWAYS/WEAK UPTREND | Medium | Price above SMA 50 ($10.58) but weak; SMA 20/50 convergence indicates trend exhaustion | | Long-term (3-12 months) | UPTREND | High | Price $9.96 well above SMA 200 ($9.27), indicating longer-term strength; 7.5% premium to 200-day average |
Interpretation: The stock exhibits a three-tier breakdown: post-rally pullback in short-term, consolidation in medium-term, and structural uptrend intact long-term. Current price action suggests mean reversion toward the SMA 50 ($10.58) or further testing of support.
Support/Resistance Levels
| Level | Price | Type | Strength | Implication | |-------|-------|------|----------|------------| | Immediate Support | $10.04 | Bollinger Lower Band | Medium | Psychology level; 0.8% below current price | | Strong Support | $10.58 | SMA 50 | High | 6.2% below current; historically tested multiple times | | Key Support | $9.27 | SMA 200 | Very High | Major technical level; 7.0% downside; long-term trend anchor | | Resistance (Near) | $11.01 | SMA 20 | Medium | Immediate barrier; 10.5% overhead | | Resistance (Strong) | $11.97 | Bollinger Upper Band | High | Recent swing high area; 20.3% upside to 52-week range upper bound |
Volume-Weighted Analysis: Volume has declined 21.13% (rate of change), suggesting diminishing buying pressure and potential for a move toward support levels.
Momentum Signals
RSI (14): 39.31 - NEUTRAL with Slight Bearish Bias
- Reading of 39.31 sits in neutral territory (30-70 range) but closer to oversold threshold (30)
- This is not yet oversold, but indicates momentum is weakening and capitulation may not be complete
- Suggests further downside possible before bounce; RSI below 30 would signal classic buy setup
MACD: -0.03 / Signal: -0.17 / Histogram: +0.14 - BULLISH DIVERGENCE
- MACD is negative but histogram is positive (+0.14), indicating MACD is rising toward signal line
- This represents a bullish crossover in formation — the first technical bullish signal despite price weakness
- Timing: Early-stage reversal signal; typically precedes price recovery by 1-3 trading days
- Conflict Alert: MACD bullish while price makes lower lows suggests potential accumulation
Stochastic: %K at 7.37, %D at 15.36 - EXTREME OVERSOLD
- %K of 7.37 is deeply oversold (readings <20 are extreme)
- Slow stochastic %D at 15.36 also severely depressed
- This represents classic oversold capitulation, historically followed by 3-5 day bounce
- Data Quality Note: This extreme reading combined with Williams %R of -97.61 suggests selling exhaustion
Bollinger Bands Analysis
- Current Position: Price $9.96 sits 3.9% above lower band ($10.04) — in the oversold zone
- Band Width: 17.56% indicates bands are moderately compressed (not at historical extremes)
- Signal Interpretation:
- Stock is oversold but not at band extreme — suggests more downside possible to reach mean reversion
- Next technical level is SMA 50 at $10.58 (6.2% higher) for mean reversion
- Squeeze Breakout Risk: If bands compress further with price consolidating, potential for sharp directional move
Volume Analysis
Volume Trends:
- 20-day SMA: 2,039,216 shares
- Rate of Change: -21.13% (declining volume trend)
- OBV: 61,212,741.64 (positive but not confirming upside)
Interpretation:
- Declining volume on downside is constructive — suggests institutional selling has diminished
- Volume-weighted negative: Lower volume on rally attempts indicates lack of conviction
- Institutional Interest Signal: OBV trending positive despite price weakness suggests accumulation by informed buyers at lower prices; typical of biotech pre-catalyst positioning
News & Sentiment Analysis
Recent Headlines Summary
| Date | Headline | Sentiment | Relevance | |------|----------|-----------|-----------| | 2026-10-15 | Gilead Deal: Oncology Pipeline Boost | POSITIVE | IMMEDIATE CATALYST - Partnership validates pipeline | | 2026-05-23 | $6M Biotech Fund Position During 99% Rally | POSITIVE | Historical context of rally; fund accumulation signal | | 2026-05-14 | Cold Tumor Immunotherapy Proving Ground | POSITIVE | Clinical development validation | | 2026-04-12 | CEO Sells 73,000 Shares ($664K) | POSITIVE (neutral data) | Insider selling at lower prices; conflicting signal | | 2026-02-24 | Market Index Commentary | POSITIVE (macro) | Broad market context; minimal direct relevance |
Sentiment Assessment
Aggregate Sentiment: POSITIVE BIAS (80% positive headlines)
However, sentiment scoring masks timing disconnect:
- Positive news (Gilead deal, immunotherapy focus) emerged in May-October 2026
- Stock appears to have rallied hard into October news, now pulling back (suggests rally exhausted)
- CEO insider selling (2026-04-12) at lower prices is historically neutral-to-bullish, but followed by a 99% run suggests near-peak positioning
Catalyst Identification
Immediate Catalysts (1-7 days):
- None identified in current data window
Near-term Catalysts (1-4 weeks):
- Earnings Release: November 4, 2026 — 9 calendar days away
- Options market pricing $1.50 expected move (35 DTE), suggesting market expects 15% volatility around print
- Recent earnings pattern (8/5, 5/6, 1/12) shows quarterly reporting cadence
- Risk: Current pullback may be pre-earnings profit-taking; earnings beat could trigger recovery
Medium-term Catalysts (1-3 months):
- Gilead partnership progress/milestones
Generated
News
All VIR news →
Earnings History
19 of 23 under expected move
Avg Expected Move
15.17%
Avg Actual Move
8.24%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 13.41% | 2.31% | 0.17x | Within |
| 2021-05-06 | After-Close | 11.78% | 3.27% | 0.28x | Within |
| 2021-08-05 | After-Close | 5.97% | 1.62% | 0.27x | Within |
| 2021-11-04 | After-Close | 16.09% | 14.78% | 0.92x | Within |
| 2022-02-24 | After-Close | 22.50% | 1.38% | 0.06x | Within |
| 2022-05-05 | After-Close | 20.39% | 3.55% | 0.17x | Within |
| 2022-08-09 | After-Close | 12.14% | 6.28% | 0.52x | Within |
| 2022-11-03 | After-Close | 7.80% | 17.71% | 2.27x | Exceeded |
| 2023-02-23 | After-Close | 11.74% | 10.91% | 0.93x | Within |
| 2023-05-04 | After-Close | 11.33% | 3.92% | 0.35x | Within |
| 2023-07-20 | After-Close | 11.65% | 12.99% | 1.12x | Exceeded |
| 2023-11-02 | After-Close | 15.63% | 6.96% | 0.45x | Within |
| 2024-02-22 | After-Close | 14.85% | 11.94% | 0.80x | Within |
| 2024-05-02 | After-Close | 16.56% | 13.18% | 0.80x | Within |
| 2024-08-01 | After-Close | 13.62% | 5.34% | 0.39x | Within |
| 2024-10-31 | After-Close | 15.69% | 23.63% | 1.51x | Exceeded |
| 2025-02-26 | After-Close | 20.92% | 11.85% | 0.57x | Within |
| 2025-05-07 | After-Close | 19.61% | 3.57% | 0.18x | Within |
| 2025-08-06 | After-Close | 9.35% | 14.37% | 1.54x | Exceeded |
| 2025-11-05 | Pre-Market | 26.67% | 2.86% | 0.11x | Within |
| 2026-01-12 | After-Close | 17.74% | 6.59% | 0.37x | Within |
| 2026-05-06 | After-Close | 15.55% | 9.91% | 0.64x | Within |
| 2026-08-05 | Pre-Market | 17.99% | 0.65% | 0.04x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VIR Options Activity & IV Rank
VIR IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 99.7%
7-DTE IV: —
Expected Move: $2.03
7-DTE Move: $2.03
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 94
Put Volume: 22
P/C Volume: 0.234
BULLISH
Call OI: 1,313
Put OI: 554
P/C OI: 0.422
Total OI: 1,867
ATM Options Pricing
ATM Call: $1.35
ATM Put: $0.68
Call %: 13.2%
Put %: 6.6%
Chain Summary
Chain Volume: 824
Chain OI: 10,626
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 64th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
64%
vs own history
GEX tilt
+0.52
OI-weighted, today
Vanna tilt
+0.88
δ-sensitivity to IV
Charm tilt
-0.90
δ-decay vs time
Vanna tilt +0.88: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.90: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 13 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 88.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)65.0MediumOct 22
Straddle Price (30 DTE)$2.03Oct 22
Beta Analysis
Risk Metrics
Beta: 1.7196
Alpha: 47.70%
Correlation: 0.3383
R-Squared: 11.4%
Stock Volatility: 64.9%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own VIR
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $57.7M | #288 of 1945 | +190.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $10.4M | #1040 of 3138 | +33.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $10.1M | #1587 of 6285 | -52.8% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $489K | #3177 of 3716 | -90.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $400K | #2209 of 4729 | -0.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VIR Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 148,421,632 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$4.11M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.02M | 24.80% | 2026-06-30 |
| 2 | NOMURA HOLDINGS INC | $979.26K | 23.85% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $543.13K | 13.23% | 2026-06-30 |
| 4 | Citigroup Inc. Custodian | $509.50K | 12.41% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $430.02K | 10.47% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $347.48K | 8.46% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $232.33K | 5.66% | 2026-06-30 |
| 8 | Walleye Capital LLC | $45.85K | 1.12% | 2026-06-30 |
5 filers$1.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | NOMURA HOLDINGS INC | $979.26K | 49.58% | 2026-06-30 |
| 2 | Citigroup Inc. Custodian | $509.50K | 25.80% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $374.99K | 18.99% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $97.96K | 4.96% | 2025-09-30 |
| 5 | Simplex Trading, LLC Custodian | $13.25K | 0.67% | 2026-06-30 |
VIR Insider Trading (Form 4)
Latest: 2026-08-12Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-12 | Robert J More | Director | Other (J) | 8,000 (reclass) | — | EDGAR | |
| 2026-06-10 | Timothy Coughlin | Director | Award (A) | +16,000 | — | EDGAR | |
| 2026-06-02 | Janet Napolitano | Director | Sell (S) | −3,200 | $9.45 | -$30.2K | EDGAR |
| 2026-06-02 | Brent Sabatini | SVP, Chief Accounting Officer | Sell (S) | −379 | $9.45 | -$3.6K | EDGAR |
| 2026-05-28 | Jeffrey S. Hatfield | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-28 | Norbert W Bischofberger | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-28 | Charles Elliott Sigal | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-28 | Ramy Farid | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-28 | Robert J More | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-28 | Janet Napolitano | Director | Award (A) | +8,000 | — | EDGAR | |
| 2026-05-04 | Vicki L Sato | Director | Sell (S) | −22,000 | $10.05 | -$221.0K | EDGAR |
| 2026-04-07 | Marianne De Backer | President and CEO | Sell (S) | −72,559 | $9.16 | -$664.4K | EDGAR |
| 2026-04-02 | Vicki L Sato | Director | Sell (S) | −22,000 | $9.07 | -$199.6K | EDGAR |
| 2026-03-24 | Brent Sabatini | SVP, Chief Accounting Officer | Sell (S) | −7,711 | $9.12 | -$70.3K | EDGAR |
| 2026-03-23 | Jason O'Byrne | EVP & Chief Financial Officer | Other (J) | 2,500 (reclass) | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VIR Insider Holdings
18 insiders · @ $10.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | 14,574,083 | $149.31M | -$202.50M | 24 | 2025-10-30 |
| 2 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | 13,728,924 | $140.65M | -$302.85M | 34 | 2025-12-03 |
| 3 | George A Scangos | Director | 1,296,509 | $13.28M | -$3.09M | 14 | 2025-02-25 |
| 4 | Vicki L Sato | Director | 1,078,391 | $11.05M | -$13.98M | 43 | 2026-05-04 |
| 5 | Marianne De Backer | President and CEO | 1,001,263 | $10.26M | -$2.26M | 9 | 2026-04-07 |
| 6 | Robert J More | Director | 558,573 | $5.72M | -$3.44M | 21 | 2026-08-12 |
| 7 | Jason O'Byrne | EVP & Chief Financial Officer | 162,615 | $1.67M | -$68.9K | 6 | 2026-03-23 |
| 8 | Mark Eisner | EVP and Chief Medical Officer | 155,913 | $1.60M | -$106.3K | 5 | 2026-02-26 |
| 9 | Ann M. Hanly | EVP & Chief Technology Officer | 117,912 | $1.21M | -$472.7K | 9 | 2025-02-25 |
| 10 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | 112,982 | $1.16M | -$411.1K | 9 | 2026-02-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VIR Board & Officers
As of SEC filings through Oct 6, 2026Directors 9
- Robert J More · since Oct 10, 2019
- Vicki L Sato · since Oct 10, 2019
- Charles Elliott Sigal · since Jul 10, 2020
- Janet Napolitano · since Aug 28, 2020
- Jeffrey S. Hatfield · since Dec 9, 2020
- Marianne De Backer · listed since Feb 2024
- Norbert W Bischofberger · since May 29, 2024
- Ramy Farid · since May 29, 2024
- Timothy Coughlin · since Jun 9, 2026
Officers 4
- Marianne De Backer · President and CEO · listed since Apr 2026
- Aziz Sawaf · EVP, Chief Financial Officer · since Oct 5, 2026
- Brent Sabatini · SVP, Chief Accounting Officer · since Oct 1, 2024
- Vanina de Verneuil · EVP, General Counsel, Corp Sec · listed since Nov 2025
Changes in the last 10 years (95)
| Oct 5, 2026 | Aziz Sawaf became EVP, Chief Financial Officer |
| Jun 9, 2026 | Timothy Coughlin became a director |
| May 25, 2026 | The company announced the departure of Saira Ramasastry from the board in an SEC filing |
| Apr 7, 2026 | The company announced the departure of Mark Eisner as EVP and Chief Medical Officer in an SEC filing |
| Apr 7, 2026 | Marianne De Backer listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Dec 3, 2025 | Softbank Vision Fund (aiv M1) L.p. reported in an SEC filing no longer being a 10% owner |
| Dec 3, 2025 | Sb Investment Advisers (uk) Ltd reported in an SEC filing no longer being a 10% owner |
| Dec 3, 2025 | SVF Endurance (Cayman) Ltd reported in an SEC filing no longer being a 10% owner |
| Nov 7, 2025 | Vanina de Verneuil listed as EVP, General Counsel, Corp Sec (previously EVP and General Counsel) in SEC filings |
| Jan 24, 2025 | The company announced the departure of Ann M. Hanly as EVP & Chief Technology Officer in an SEC filing |
| Oct 2, 2024 | Jason O'Byrne became EVP & Chief Financial Officer |
| Oct 1, 2024 | Vanina de Verneuil became EVP and General Counsel |
| Oct 1, 2024 | Brent Sabatini became SVP, Chief Accounting Officer |
| Jun 3, 2024 | Mark Eisner became EVP and Chief Medical Officer |
| May 29, 2024 | Ramy Farid became a director |
| May 29, 2024 | Norbert W Bischofberger became a director |
| Apr 15, 2024 | The company announced the departure of Sung Lee as EVP & Chief Financial Officer in an SEC filing |
| Feb 26, 2024 | Sung Lee listed as EVP & Chief Financial Officer (previously Chief Financial Officer) in SEC filings |
| Feb 26, 2024 | Marianne De Backer first listed as a director in an SEC filing |
| Feb 26, 2024 | Ann M. Hanly listed as EVP & Chief Technology Officer (previously Chief Technology Officer) in SEC filings |
| Feb 20, 2024 | The company announced the departure of Phillip Pang as EVP & Chief Medical Officer in an SEC filing |
| Jan 3, 2024 | Phillip Pang listed as EVP & Chief Medical Officer (previously Chief Medical Officer) in SEC filings |
| Sep 20, 2023 | The company announced the departure of Johanna Friedl-Naderer as EVP & Chief Operating Officer in an SEC filing |
| Apr 3, 2023 | Marianne De Backer became Chief Executive Officer |
| Mar 27, 2023 | Sung Lee became Chief Financial Officer |
| Feb 24, 2023 | Johanna Friedl-Naderer listed as EVP & Chief Operating Officer (previously Chief Business Officer, Global) in SEC filings |
| Feb 13, 2023 | The company announced the departure of Howard Horn as CFO in an SEC filing |
| Jan 19, 2023 | The company announced the departure of George A Scangos as President and CEO in an SEC filing |
| Sep 7, 2022 | Keith Crandell reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | Clinton Bybee reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | ARCH Venture Partners IX, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | ARCH Venture Partners IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | ARCH Venture Partners IX Overage, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | ARCH Venture Fund IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 7, 2022 | ARCH Venture Fund IX Overage, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 11, 2022 | The company announced the departure of Herbert Virgin as EVP, Research & CSO in an SEC filing |
| Mar 2, 2022 | Johanna Friedl-Naderer became Chief Business Officer, Global |
| Mar 29, 2021 | Ann M. Hanly became Chief Technology Officer |
| Dec 9, 2020 | Jeffrey S. Hatfield became a director |
| Oct 13, 2020 | Kristina Burow reported in an SEC filing no longer being a director |
| Aug 28, 2020 | Janet Napolitano became a director |
| Jul 30, 2020 | Steven J. Rice became Chief Administrative Officer |
| Jul 10, 2020 | Charles Elliott Sigal became a director |
| Oct 18, 2019 | Temasek Life Sciences Private Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Temasek Holdings (Private) Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | TLS Beta Pte. Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Q-Ventures Program II (Co-Invest Holdings) Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Platinum International Investment Holding RSC Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Platinum Falcon B 2018 RSC Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Klaus Frueh reported in an SEC filing no longer being a director |
| Oct 18, 2019 | Fullerton Management Pte Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Frank G. Angella reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Christopher Quinn reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2019 | Abu Dhabi Investment Authority reported in an SEC filing no longer being a 10% owner |
| Oct 16, 2019 | Bill & Melinda Gates Foundation reported in an SEC filing no longer being a 10% owner |
| Oct 16, 2019 | Alaska Permanent Fund Corp reported in an SEC filing no longer being a 10% owner |
| Oct 10, 2019 | Vicki L Sato became a director |
| Oct 10, 2019 | Temasek Life Sciences Private Ltd became a 10% owner |
| Oct 10, 2019 | Temasek Holdings (Private) Ltd became a 10% owner |
| Oct 10, 2019 | TLS Beta Pte. Ltd. became a 10% owner |
| Oct 10, 2019 | Softbank Vision Fund (aiv M1) L.p. became a 10% owner |
| Oct 10, 2019 | Sb Investment Advisers (uk) Ltd became a 10% owner |
| Oct 10, 2019 | Saira Ramasastry became a director |
| Oct 10, 2019 | SVF Endurance (Cayman) Ltd became a 10% owner |
| Oct 10, 2019 | Robert Nelsen became a director |
| Oct 10, 2019 | Robert Nelsen became a 10% owner |
| Oct 10, 2019 | Robert J Perez became a director |
| Oct 10, 2019 | Robert J More became a director |
| Oct 10, 2019 | Q-Ventures Program II (Co-Invest Holdings) Ltd. became a 10% owner |
| Oct 10, 2019 | Platinum International Investment Holding RSC Ltd became a 10% owner |
| Oct 10, 2019 | Platinum Falcon B 2018 RSC Ltd became a 10% owner |
| Oct 10, 2019 | Phillip Pang became Chief Medical Officer |
| Oct 10, 2019 | Phillip A Sharp became a director |
| Oct 10, 2019 | Michael E. Kamarck became Chief Technology Officer |
| Oct 10, 2019 | Kristina Burow became a director |
| Oct 10, 2019 | Klaus Frueh became a director |
| Oct 10, 2019 | Keith Crandell became a 10% owner |
| Oct 10, 2019 | Jay Parrish became Chief Business Officer |
| Oct 10, 2019 | Howard Horn became CFO |
| Oct 10, 2019 | Herbert Virgin became EVP, Research & CSO |
| Oct 10, 2019 | George A Scangos became a director |
| Oct 10, 2019 | George A Scangos became President and CEO |
| Oct 10, 2019 | Fullerton Management Pte Ltd became a 10% owner |
| Oct 10, 2019 | Frank G. Angella became a 10% owner |
| Oct 10, 2019 | Dipchand Nishar became a director |
| Oct 10, 2019 | Clinton Bybee became a 10% owner |
| Oct 10, 2019 | Christopher Quinn became a 10% owner |
| Oct 10, 2019 | Bill & Melinda Gates Foundation became a 10% owner |
| Oct 10, 2019 | Alaska Permanent Fund Corp became a 10% owner |
| Oct 10, 2019 | Abu Dhabi Investment Authority became a 10% owner |
| Oct 10, 2019 | ARCH Venture Partners IX, LLC became a 10% owner |
| Oct 10, 2019 | ARCH Venture Partners IX, L.P. became a 10% owner |
| Oct 10, 2019 | ARCH Venture Partners IX Overage, L.P. became a 10% owner |
| Oct 10, 2019 | ARCH Venture Fund IX, L.P. became a 10% owner |
| Oct 10, 2019 | ARCH Venture Fund IX Overage, L.P. became a 10% owner |
Not reported recently (9)
- Jason O'Byrne · Last reported as EVP & Chief Financial Officer in an SEC filing dated Mar 23, 2026
- George A Scangos · Last reported as a director in an SEC filing dated Feb 25, 2025
- Robert Nelsen · Last reported as a director in an SEC filing dated Jun 3, 2024
- Steven J. Rice · Last reported as Chief Administrative Officer in an SEC filing dated Jun 2, 2023
- Phillip A Sharp · Last reported as a director in an SEC filing dated May 24, 2023
- Robert J Perez · Last reported as a director in an SEC filing dated May 24, 2023
- Dipchand Nishar · Last reported as a director in an SEC filing dated May 25, 2021
- Jay Parrish · Last reported as Chief Business Officer in an SEC filing dated Apr 5, 2021
- Michael E. Kamarck · Last reported as Chief Technology Officer in an SEC filing dated Oct 10, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VIR Proposed Insider Sales (Form 144)
Latest: 2026-09-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
5 filings
· $1.2M notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
O'Byrne Jason (5, $1.2M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-17 | O'Byrne Jason | Former Officer | 19,357 | $212.9K | 2026-09-17 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-09 | O'Byrne Jason | Former Officer | 28,333 | $315.2K | 2026-09-09 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-25 | O'Byrne Jason | Former Officer | 23,148 | $242.6K | 2026-08-25 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-24 | O'Byrne Jason | Former Officer | 14,352 | $142.1K | 2026-08-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-21 | O'Byrne Jason | Former Officer | 25,000 | $245.3K | 2026-08-21 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-29 | Ramasastry Saira | Former Director | 16,000 | $165.1K | 2026-06-29 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-01 | Sabatini Brent | Officer | 379 | $3.6K | 2026-06-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-01 | Napolitano Janet | Director | 3,200 | $30.2K | 2026-06-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-04-30 | Eisner Mark | Former Officer | 88,958 | $916.3K | 2026-04-30 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-04-06 | De Backer Marianne | Officer, Director | 72,559 | $664.3K | 2026-04-06 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
87 ETFs hold VIR
25 shown · $406.87M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.08% | $81.1M | $103.1B | 2026-10-20 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $54.5M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $38.3M | — | 2026-09-30 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.05% | $37.2M | $75.1B | 2026-10-20 |
| 5 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.27% | $28.5M | $10.4B | 2026-10-20 |
| 6 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.05% | $21.3M | — | 2026-09-30 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $16.0M | — | 2026-09-30 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.10% | $13.6M | $13.7B | 2026-10-20 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.04% | $12.8M | — | 2026-10-20 |
| 10 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.08% | $12.4M | $15.7B | 2026-10-20 |
| 11 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.10% | $11.0M | $11.0B | 2026-10-20 |
| 12 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.05% | $8.9M | — | 2026-09-30 |
| 13 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.62% | $8.3M | $1.3B | 2026-10-20 |
| 14 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $7.2M | — | 2026-10-20 |
| 15 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.09% | $6.6M | $7.6B | 2026-10-20 |
| 16 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.10% | $6.3M | $6.6B | 2026-10-20 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.07% | $5.6M | — | 2026-10-20 |
| 18 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.07% | $5.2M | $7.6B | 2026-10-20 |
| 19 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $5.1M | — | 2026-05-31 |
| 20 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.08% | $5.0M | — | 2026-09-30 |
| 21 | JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | JPMorgan | 0.17% | $4.8M | $2.9B | 2026-10-21 |
| 22 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.6M | — | 2026-09-30 |
| 23 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.09% | $4.3M | $4.7B | 2026-10-20 |
| 24 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.30% | $4.1M | $1.4B | 2026-10-20 |
| 25 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 1.25% | $4.0M | $325.4M | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.85
TTM Revenue
$303.23M
TTM Net Income
$-251.68M
TTM Op. Cash Flow
$-202.51M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $238.95M | $80.08M | $0.47 | $123.33M |
| Q4 '25 | 2025-12-31 | $64.07M | $-42.92M | $-0.30 | $-25.88M |
| Q3 '25 | 2025-09-30 | $240.00K | $-163.14M | $-1.17 | $-167.57M |
| Q2 '25 | 2025-06-30 | $1.21M | $-110.96M | $-0.80 | $-120.22M |
| Q1 '25 | 2025-03-31 | $3.03M | $-120.97M | $-0.88 | $-78.12M |
| Q4 '24 | 2024-12-31 | $12.37M | $-104.59M | $-0.76 | $-87.64M |
| Q3 '24 | 2024-09-30 | $2.38M | $-213.72M | $-1.56 | $-171.48M |
| Q2 '24 | 2024-06-30 | $3.08M | $-138.38M | $-1.02 | $-77.85M |
| Q1 '24 | 2024-03-31 | $56.38M | $-65.28M | $-0.48 | $-109.39M |
| Q4 '23 | 2023-12-31 | $16.79M | $-115.97M | $-0.86 | $-107.93M |
| Q3 '23 | 2023-09-30 | $2.64M | $-163.41M | $-1.22 | $-155.83M |
| Q2 '23 | 2023-06-30 | $3.80M | $-194.78M | $-1.45 | $-389.25M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.55
P/S
5.01
EV/EBITDA
—
EV/Sales
4.09
ROE
-25.6%
ROA
-20.7%
Div Yield
0.00%
FCF Yield
-13.32%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.52B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
14.98M
SI % of Float
11.34%
Days to Cover
7.01
Short Vol Ratio
67.1%
Free Float
132.16M
Float %
78.1%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14